The Patented Medicines Pricing Review Board in Canada has released its annual report for 2017.
It reported a moderate 7.6% increase in sales over the previous year, with prices not increasing. Canadian price levels are mid-ranked against reference countries, at approximately 5% more than the UK and 25% more than France, but 10% less than Germany.
The organisation reviewed the prices of 59 of the 80 medicines new in 2017, and found 11 exceeded its price guidelines. Of these 5 have resulted in negotiated price-reduction agreements (VCUs).
R&D expenditure from companies working through PMPRB fell 5% to $870 million, falling from 4.4% of sales to 4.1%.
The full report can be found here.